Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

TRAF1 antibody (AA 73-219)

The Mouse Monoclonal anti-TRAF1 antibody has been validated for IHC and StM. It is suitable to detect TRAF1 in samples from Human.
Catalog No. ABIN6940806

Quick Overview for TRAF1 antibody (AA 73-219) (ABIN6940806)

Target

See all TRAF1 Antibodies
TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

Reactivity

  • 71
  • 34
  • 19
  • 3
  • 3
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
Human

Host

  • 47
  • 27
  • 1
Mouse

Clonality

  • 50
  • 25
Monoclonal

Conjugate

  • 34
  • 4
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This TRAF1 antibody is un-conjugated

Application

  • 33
  • 27
  • 19
  • 18
  • 13
  • 13
  • 5
  • 5
  • 3
  • 3
  • 2
  • 1
  • 1
  • 1
Immunohistochemistry (IHC), Staining Methods (StM)

Clone

TRAF1-3298
  • Binding Specificity

    • 21
    • 15
    • 8
    • 6
    • 3
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    AA 73-219

    Specificity

    This MAb recognizes a protein of 52 kDa, which is identified as TNFR1 (TNFR-associated factor 1). CD30-positive lymphoproliferations of the skin comprise 30 % of all primary cutaneous T-cell lymphomas (CTCLs). Besides borderline cases this group includes lymphomatoid papulosis (LyP) and primary cutaneous anaplastic large T-cell lymphoma (cALCL). Although the two entities overlap clinically, histopathologically, immunopathologically and genetically, they differ considerably in their prognosis. In particular, common feature of both cases is histologically the presence of atypical lymphoid CD30-positive T blasts and genetically a clonal T-cell-receptor rearrangement. However, both cases differ considerably in their clinical course: Lesions of LyP regress spontaneously, whereas those of cALCL persist and may progress and spread. Moreover, LyP patients do not benefit from an aggressive radio- and/or chemotherapeutic approach, in contrast to patients with cALCL. Besides, LyP and cALCL differ strongly in the expression of TRAF1 (tumor necrosis factor receptor (TNFR)-associated factor 1), a component of TNFR signaling: Whereas tumor cells of most LyP cases (ca. 84 %) show a strong TRAF1 expression, tumor cells of cALCL reveal TRAF1 expression in only a few cases (ca. 7 %). Antibody to TRAF1 is highly useful for the differentiation of LyP and cALCL in patients with cutaneous CD30-positive lymphoproliferations.

    Purification

    Purified by Protein A/G

    Immunogen

    Recombinant fragment of human TRAF1 protein (around aa 73-219) (exact sequence is proprietary)

    Isotype

    IgG2b kappa
  • Application Notes

    Positive Control: HeLa or 293T cells. Hodgkin s Lymphoma (IHC).

    Known Application: Immunohistochemistry (Formalin-fixed) (1-2 μg/mL for 30 minutes at RT) ,(Staining of formalin-fixed tissues requires boiling tissue sections in 10 mM citrate buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes),Optimal dilution for a specific application should be determined.

    Restrictions

    For Research Use only
  • Concentration

    200 μg/mL

    Buffer

    10 mM PBS with 0.05 % BSA & 0.05 % azide.

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-80 °C

    Storage Comment

    Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.

    Expiry Date

    24 months
  • Target

    TRAF1 (TNF Receptor-Associated Factor 1 (TRAF1))

    Alternative Name

    TRAF1

    Molecular Weight

    52kDa

    Gene ID

    7185

    UniProt

    Q13077

    Pathways

    NF-kappaB Signaling, Apoptosis, Cell-Cell Junction Organization, Asymmetric Protein Localization
You are here:
Chat with us!